Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Capital Leases (2016 - 2018)

Historic Capital Leases for Seres Therapeutics (MCRB) over the last 4 years, with Q4 2018 value amounting to $6.8 million.

  • Seres Therapeutics' Capital Leases fell 2461.9% to $6.8 million in Q4 2018 from the same period last year, while for Dec 2018 it was $6.8 million, marking a year-over-year decrease of 2461.9%. This contributed to the annual value of $6.8 million for FY2018, which is 2461.9% down from last year.
  • Per Seres Therapeutics' latest filing, its Capital Leases stood at $6.8 million for Q4 2018, which was down 2461.9% from $7.7 million recorded in Q3 2018.
  • In the past 5 years, Seres Therapeutics' Capital Leases registered a high of $10.7 million during Q3 2016, and its lowest value of $586000.0 during Q4 2015.
  • Over the past 4 years, Seres Therapeutics' median Capital Leases value was $9.0 million (recorded in 2017), while the average stood at $8.1 million.
  • Its Capital Leases has fluctuated over the past 5 years, first skyrocketed by 173105.8% in 2016, then crashed by 2461.9% in 2018.
  • Quarter analysis of 4 years shows Seres Therapeutics' Capital Leases stood at $586000.0 in 2015, then soared by 1731.06% to $10.7 million in 2016, then fell by 16.23% to $9.0 million in 2017, then decreased by 24.62% to $6.8 million in 2018.
  • Its Capital Leases was $6.8 million in Q4 2018, compared to $7.7 million in Q3 2018 and $8.1 million in Q2 2018.